Background: Vilazodone is an antidepressant with selective serotonin reuptake inhibition
and partial 5HT1A agonism. Serotonin syndrome is believed to be due to excessive …

Background: Unintentional ingestion of selective serotonin reuptake inhibitor (SSRI)
medications is common amongst children< 6 years of age. Current evidence-based …

Vilazodone (Viibryd; Forest Laboratories, Inc., New York, NY) is a novel antidepressant
approved by the Food and Drug Administration in 2011 for the treatment of depression. It …

Background Vilazodone is a selective serotonin reuptake inhibitor and 5HT 1A agonist
recently approved to treat depression in adults. To date, there are minimal data available …

Background: Selective serotonin reuptake inhibitor (SSRI) exposures among children
younger than 6 years of age are generally well tolerated. Vilazodone is an SSRI with partial …

Vilazodone hydrochloride is the first member in a new class of antidepressants called
indolealkylamines and was approved for use in the United States in 2011 for major …

Background Vilazodone was approved by the US Food and Drug Administration in 2011 as
a treatment for major depression disorder. Vilazodone is a selective serotonin reuptake …

Vilazodone is a selective serotonin reuptake inhibitor (SSRI) that was introduced to the
market in 2011. It has a novel mechanism combining serotonin reuptake and partial …

There is a deficiency in published literature describing serotonin syndrome with standard
vilazodone (Viibryd< sup>) treatment. This is the case of a 28-year-old female with anxiety …

Serotonin syndrome (SS) is a serious toxicity that manifests with symptoms such as tremor,
hyperthermia, agitation, and altered mental status that may lead to seizures, coma, or death …